文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

体外膜氧合用于伴呼吸衰竭的难治性哮喘急性发作

Extracorporeal Membrane Oxygenation for Refractory Asthma Exacerbations With Respiratory Failure.
PubMed 文献 · Chest · 2022-09-30
一句话结论回顾性队列研究显示,对需有创通气的难治性哮喘急性发作,ECMO与住院死亡率降低相关(校正OR 0.33),但住院费用更高,尚待确证性临床试验。

该研究利用2010至2020年美国全国行政数据集(覆盖25%住院病例),纳入在具备ECMO能力医院接受短效支气管扩张剂、全身糖皮质激素和有创通气的哮喘急性发作成人患者,排除年龄<18岁、无ICU入住、非哮喘慢性肺病、COVID-19或多次入院者,比较ECMO与无ECMO的住院死亡率。共分析13,714例,其中ECMO组127例、无ECMO组13,587例;ECMO与死亡率降低相关(协变量校正OR 0.33,95%CI 0.17-0.64,P=.001;倾向评分校正OR 0.36,95%CI 0.16-0.81,P=.01;倾向评分匹配OR 0.48,95%CI 0.24-0.98,P=.04),敏感性分析OR 0.34-0.61。ECMO组住院费用更高(三项模型均P<.0001),但ICU住院时长、住院时长和有创通气时间无减少。作者认为ECMO可能是难治性哮喘急性发作伴呼吸衰竭的重要挽救治疗,尚需确证性临床试验。

要点

  • 在需有创通气的难治性哮喘急性发作成人中,ECMO与住院死亡率降低相关:协变量校正OR 0.33(95%CI 0.17-0.64,P=.001)。
  • 倾向评分校正OR 0.36(95%CI 0.16-0.81,P=.01)、倾向评分匹配OR 0.48(95%CI 0.24-0.98,P=.04),敏感性分析OR 0.34-0.61。
  • ECMO组住院费用更高(三项模型均P<.0001),但ICU住院时长、住院时长和有创通气时间未见减少。
  • 作者认为ECMO可能是难治性哮喘急性发作伴呼吸衰竭的重要挽救治疗,但需确证性临床试验。

适用人群与场景

  • 纳入:入住具备ECMO能力医院的哮喘急性发作患者,且接受短效支气管扩张剂、全身糖皮质激素和有创通气。
  • 排除:年龄<18岁、无ICU入住、非哮喘慢性肺病、COVID-19、多次入院。

研究设计与关键结果

  • 研究类型:回顾性、流行病学、观察性队列研究,使用2010至2020年美国全国行政数据集,覆盖25%美国住院病例。
  • 共分析13,714例伴呼吸衰竭的哮喘急性发作患者,其中ECMO组127例、无ECMO组13,587例。
  • 主要终点住院死亡率:ECMO vs 无ECMO,协变量校正OR 0.33(95%CI 0.17-0.64,P=.001);倾向评分校正OR 0.36(95%CI 0.16-0.81,P=.01);倾向评分匹配OR 0.48(95%CI 0.24-0.98,P=.04)。
  • 敏感性分析显示ECMO相关死亡率降低范围为OR 0.34至0.61。
  • 关键次要终点:ECMO与住院费用增加相关(三项模型均P<.0001),但与ICU住院时长、住院时长或有创通气时间减少无关。

证据类型、等级与局限

  • 证据类型:回顾性、流行病学、观察性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为ECMO可能是难治性哮喘急性发作伴呼吸衰竭的重要挽救治疗,但需确证性临床试验。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Asthma exacerbations with respiratory failure (AERF) are associated with hospital mortality of 7% to 15%. Extracorporeal membrane oxygenation (ECMO) has been used as a salvage therapy for refractory AERF, but controlled studies showing its association with mortality have not been performed.

RESEARCH QUESTION: Is treatment with ECMO associated with lower mortality in refractory AERF compared with standard care?

STUDY DESIGN AND METHODS: This is a retrospective, epidemiologic, observational cohort study using a national, administrative data set from 2010 to 2020 that includes 25% of US hospitalizations. People were included if they were admitted to an ECMO-capable hospital with an asthma exacerbation, and were treated with short-acting bronchodilators, systemic corticosteroids, and invasive ventilation. People were excluded for age < 18 years, no ICU stay, nonasthma chronic lung disease, COVID-19, or multiple admissions. The main exposure was ECMO vs No ECMO. The primary outcome was hospital mortality. Key secondary outcomes were ICU length of stay (LOS), hospital LOS, time receiving invasive ventilation, and total hospital costs.

RESULTS: The study analyzed 13,714 patients with AERF, including 127 with ECMO and 13,587 with No ECMO. ECMO was associated with reduced mortality in the covariate-adjusted (OR, 0.33; 95% CI, 0.17-0.64; P = .001), propensity score-adjusted (OR, 0.36; 95% CI, 0.16-0.81; P = .01), and propensity score-matched models (OR, 0.48; 95% CI, 0.24-0.98; P = .04) vs No ECMO. Sensitivity analyses showed that mortality reduction related to ECMO ranged from OR 0.34 to 0.61. ECMO was also associated with increased hospital costs in all three models (P < .0001 for all) vs No ECMO, but not with decreased ICU LOS, hospital LOS, or time receiving invasive ventilation.

INTERPRETATION: ECMO was associated with lower mortality and higher hospital costs, suggesting that it may be an important salvage therapy for refractory AERF following confirmatory clinical trials.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Zakrajsek JK, Min SJ, Ho PM, et al. Extracorporeal Membrane Oxygenation for Refractory Asthma Exacerbations With Respiratory Failure. Chest. 2022. PMID: 36191634. doi:10.1016/j.chest.2022.09.029

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。